Identification
NameIMC-A12
Accession NumberDB05759
TypeBiotech
GroupsInvestigational
DescriptionIMC-A12 is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types. It is developed for the treatment of advanced solid tumors.
Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIINot Available
CAS numberNot Available
Pharmacology
IndicationInvestigated for use/treatment in colorectal cancer and prostate cancer.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionIMC-A12 is a fully human monoclonal antibody that specifically targets the type 1 human insulin-like growth factor receptor (IGF-IR). Tumors have receptors for the insulin-like growth factor-1 (IGF-I), and it is thought that the presence of these receptors cause tumors to grow. IMC-A12 attaches to the receptors and may inhibit the growth of cancer cells.
TargetKindPharmacological actionActionsOrganismUniProt ID
Insulin-like growth factor 1 receptorProteinunknownNot AvailableHumanP08069 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life148 h (3 mg/kg dose level) 209 h (6mg/kg dose level)
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with IMC-A12.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with IMC-A12.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with IMC-A12.Investigational
RindopepimutThe therapeutic efficacy of CDX-110 can be decreased when used in combination with IMC-A12.Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with IMC-A12.Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL: IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s. [PubMed:17875788 ]
  2. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. 2005 May 20;280(20):19665-72. Epub 2005 Mar 9. [PubMed:15757893 ]
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAdvanced Solid Tumors1
1CompletedTreatmentAdult Angiosarcoma / Adult Desmoplastic Small Round Cell Tumor / Adult Epithelioid Sarcoma / Adult Extraskeletal Myxoid Chondrosarcoma / Adult Extraskeletal Osteosarcoma / Adult Fibrosarcoma / Adult Leiomyosarcoma / Adult Liposarcoma / Adult Malignant Mesenchymoma / Adult Malignant Peripheral Nerve Sheath Tumor / Adult Rhabdomyosarcoma / Adult Synovial Sarcoma / Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone / Childhood Angiosarcoma / Childhood Desmoplastic Small Round Cell Tumor / Childhood Epithelioid Sarcoma / Childhood Fibrosarcoma / Childhood Leiomyosarcoma / Childhood Liposarcoma / Childhood Malignant Mesenchymoma / Childhood Malignant Peripheral Nerve Sheath Tumor / Childhood Pleomorphic Rhabdomyosarcoma / Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features / Childhood Synovial Sarcoma / Dermatofibrosarcoma Protuberans / Malignant Adult Hemangiopericytoma / Malignant Childhood Hemangiopericytoma / Metastatic Childhood Soft Tissue Sarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
1CompletedTreatmentAdult Hepatocellular Carcinoma / Advanced Adult Hepatocellular Carcinoma / Localized Non-Resectable Adult Liver Carcinoma / Recurrent Adult Liver Carcinoma1
1CompletedTreatmentAdult Solid Neoplasm1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentGastrin-Producing Neuroendocrine Tumor / Lung Carcinoid Tumor / Metastatic Digestive System Neuroendocrine Tumor G1 / Pancreatic Glucagonoma / Pancreatic Insulinoma / Pancreatic Polypeptide Tumor / Paraganglioma / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Merkel Cell Carcinoma / Recurrent Pancreatic Neuroendocrine Carcinoma / Regional Digestive System Neuroendocrine Tumor G1 / Somatostatin-Producing Neuroendocrine Tumor / Stage III Merkel Cell Carcinoma / Stage IV Merkel Cell Carcinoma / Thyroid Gland Medullary Carcinoma1
1CompletedTreatmentNeoplasms, Malignant1
1CompletedTreatmentRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentTumors1
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1WithdrawnTreatmentGliomas / Neoplasms, Brain Stem / Pinealoma1
1, 2Active Not RecruitingTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2CompletedTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1, 2CompletedTreatmentStage IV Pancreatic Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Adenocarcinomas / Esophageal Squamous Cell Carcinomas / Recurrent Esophageal Carcinoma / Stage IV Esophageal Cancer1
2Active Not RecruitingTreatmentChildhood Alveolar Soft-part Sarcoma / Childhood Angiosarcoma / Childhood Epithelioid Sarcoma / Childhood Fibrosarcoma / Childhood Gliosarcoma / Childhood Leiomyosarcoma / Childhood Liposarcoma / Childhood Neurofibrosarcoma / Childhood Synovial Sarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Osteosarcoma1
2Active Not RecruitingTreatmentExtensive Stage Small Cell Lung Cancer / Extensive Stage Small Cell Lung Carcinoma / Recurrent Small Cell Lung Cancer / Recurrent Small Cell Lung Carcinoma1
2Active Not RecruitingTreatmentHER2/Neu Positive / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2Active Not RecruitingTreatmentLung Cancers1
2Active Not RecruitingTreatmentPeritoneal Mesotheliomas / Pleural Mesotheliomas1
2CompletedTreatmentAdenocarcinoma of the Prostate1
2CompletedTreatmentAdipocytic Sarcoma / Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET) / Leiomyosarcomas / Rhabdomyosarcomas / Synovial Sarcoma1
2CompletedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
2CompletedTreatmentAdult Rhabdomyosarcoma / Adult Synovial Sarcoma / Childhood Hepatoblastoma / Childhood Synovial Sarcoma / Neuroectodermal Tumors / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Adrenocortical Carcinoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Liver Cancer / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive / Recurrent Neuroblastoma / Recurrent Osteosarcoma / Recurrent Retinoblastoma / Recurrent Wilms Tumor and Other Childhood Kidney Tumors1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Metastatic Childhood Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
2CompletedTreatmentCarcinoma of the Prostate2
2CompletedTreatmentCarcinomas / Neuroendocrine Tumors1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Ciliary Body and Choroid Melanoma, Small Size / Iris Melanoma / Metastatic Intraocular Melanoma / Recurrent Intraocular Melanoma / Stage IV Intraocular Melanoma1
2CompletedTreatmentColon Cancer / Rectal Cancers1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentHead and Neck Cancers1
2CompletedTreatmentHepatocellular Carcinomas1
2CompletedTreatmentLeukemia, Mast-Cell1
2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentMetastatic Osteosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Osteosarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentAdenocarcinoma of the Lung / Bronchioloalveolar Carcinoma / Bronchioloalveolar Lung Carcinoma / Large Cell Lung Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentRecurrent Adrenocortical Carcinoma / Stage III Adrenocortical Carcinoma / Stage IV Adrenocortical Carcinoma1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein tyrosine kinase activity
Specific Function:
Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation,...
Gene Name:
IGF1R
Uniprot ID:
P08069
Molecular Weight:
154791.73 Da
Drug created on November 18, 2007 11:27 / Updated on August 17, 2016 12:24